A Korean company established in 1978 has been No. 1 domestric company with highest yield in the field of neuropsychology. Thus, the company has produced more than 80 types of medicines for treatment of Schizopherenia, tranquilizer, antidepressant, anti-epileptic drugs, and treatment of alcoholic disease. The company is seeking for partners to develop the medicines and enter the international market under commercial agreement with technical assistance and license agreement.
A Korean company has focused on the psychiatric and neurological disease since founded in 1978, and they developed approximately 80 types of medicines including neuro-psychology therapy.
The company is seeking for technology called new CNS (Central Nervous System) active carbamate derivatives as anti-epileptic drug. The technology needs a function that it shows similar activity of anti-convulsant to racemic EMC (Electromagnetic Compatibility) in mouse and rat.
Basically, the company is thinking about active anticonvulsant with various spectrum that would be triggered prior to activity of mechanism.
With these ideas, the company is open for two cooperation types, such as license and commercial agreement with technical asisstance with partners to research in the field of pharmaceuticals.
- Type of partner sought: The Korean SME is seeking fro experts to cooperate with development in technology for innovative efficiency on neuropsychology therapy.
- Specific area of activity of the partner: - Type of partner sought: SME or Research Institute
- Specific area of activity of the partner: Pharmaceuticals, Alzheimer’s treatment
- Task to be performed: Technology of CNS (Central Nervous System) should be developed to functions as pharmacetical drugs for neuro-psychology therapy with partnership of commercial agreement with technical assistance and license agreement.
24 days ago - PREPARE FOR BREXIT - Free events & webinars
24 days ago - Funding competition: ISCF Future food production systems
34 days ago - Innovation loans: September 2019 open competition